Literature DB >> 24232373

The value of single-pathogen antibacterial agents.

Brad Spellberg1, John H Rex.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24232373      PMCID： PMC4012226          DOI： 10.1038/nrd3957-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

1.  Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life.

Authors:  D K Heyland; W Hopman; H Coo; J Tranmer; M A McColl
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

2.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

3.  A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.

Authors:  Demissie Alemayehu; John Quinn; Jack Cook; Mark Kunkel; Charles A Knirsch
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

4.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-08-13       Impact factor: 9.079

5.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

6.  A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

Authors:  John H Rex; Barry I Eisenstein; Jeff Alder; Mark Goldberger; Robert Meyer; Aaron Dane; Ian Friedland; Charles Knirsch; Wendy R Sanhai; John Tomayko; Cindy Lancaster; Jennifer Jackson
Journal:  Lancet Infect Dis       Date:  2013-01-15       Impact factor: 25.071

Review 7.  Platforms for antibiotic discovery.

Authors:  Kim Lewis
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

8.  Quality-adjusted survival in the first year after the acute respiratory distress syndrome.

Authors:  D C Angus; A A Musthafa; G Clermont; M F Griffin; W T Linde-Zwirble; T T Dremsizov; M R Pinsky
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

9.  An economic evaluation of activated protein C treatment for severe sepsis.

Authors:  Braden J Manns; Helen Lee; Christopher James Doig; David Johnson; Cam Donaldson
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  The future of antibiotics and resistance.

Authors:  Brad Spellberg; John G Bartlett; David N Gilbert
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245
  10 in total
  45 in total

1.  K2 Capsule Depolymerase Is Highly Stable, Is Refractory to Resistance, and Protects Larvae and Mice from Acinetobacter baumannii Sepsis.

Authors:  Hugo Oliveira; Ana Mendes; Alexandra G Fraga; Alice Ferreira; Andreia I Pimenta; Dalila Mil-Homens; Arsénio M Fialho; Jorge Pedrosa; Joana Azeredo
Journal:  Appl Environ Microbiol       Date:  2019-08-14       Impact factor: 4.792

2.  In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates.

Authors:  Michael D Huband; Rodrigo E Mendes; Michael A Pfaller; Jill M Lindley; Gregory J Strand; Vincent J Benn; Jay Zhang; Li Li; Min Zhang; Xiaojuan Tan; Qingmei Liu; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 3.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

5.  The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.

Authors:  Shun Xin Wang-Lin; Ruth Olson; Janet M Beanan; Ulrike MacDonald; Joseph P Balthasar; Thomas A Russo
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

6.  Narrow-Spectrum Antibacterial Agents.

Authors:  Roberta J Melander; Daniel V Zurawski; Christian Melander
Journal:  Medchemcomm       Date:  2017-11-06       Impact factor: 3.597

7.  The UDP-GalNAcA biosynthesis genes gna-gne2 are required to maintain cell envelope integrity and in vivo fitness in multi-drug resistant Acinetobacter baumannii.

Authors:  Sébastien Crépin; Elizabeth N Ottosen; Courtney E Chandler; Anna Sintsova; Robert K Ernst; Harry L T Mobley
Journal:  Mol Microbiol       Date:  2019-11-19       Impact factor: 3.501

8.  Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.

Authors:  Travis B Nielsen; Paul Pantapalangkoor; Brian M Luna; Kevin W Bruhn; Jun Yan; Ken Dekitani; Sarah Hsieh; Brandon Yeshoua; Bryan Pascual; Evgeny Vinogradov; Kristine M Hujer; T Nicholas Domitrovic; Robert A Bonomo; Thomas A Russo; Magda Lesczcyniecka; Thomas Schneider; Brad Spellberg
Journal:  J Infect Dis       Date:  2017-08-15       Impact factor: 5.226

9.  Exploiting Interkingdom Interactions for Development of Small-Molecule Inhibitors of Candida albicans Biofilm Formation.

Authors:  F Jerry Reen; John P Phelan; Lorna Gallagher; David F Woods; Rachel M Shanahan; Rafael Cano; Eoin Ó Muimhneacháin; Gerard P McGlacken; Fergal O'Gara
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa.

Authors:  Xin Zhu; Anshan Shan; Zhi Ma; Wei Xu; Jiajun Wang; Shuli Chou; Baojing Cheng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.